Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as...

Area of Science:

• Oncology
• Pharmacology

Background:

• First-line treatment for advanced non-small cell lung cancer (NSCLC) often involves Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).
• Limited head-to-head comparisons exist for various EGFR-TKI combination therapies in NSCLC.
• Evidence synthesis is needed to guide optimal first-line treatment strategies.

Purpose of the Study:

• To compare the efficacy and safety of different combination therapies with EGFR-TKIs for first-line treatment of advanced NSCLC.
• To identify which combination strategies offer the greatest benefits in progression-free survival (PFS) and overall survival (OS).
• To evaluate the safety profiles and adverse events associated with these combination therapies.

Main Methods:

• Systematic review and Bayesian network meta-analysis of randomized controlled trials (RCTs).
• Searched MEDLINE, EMBASE, and COCHRANE databases for relevant studies.
• Analyzed data on progression-free survival, overall survival, and adverse events (AEs).

Main Results:

• EGFR-TKI combined with antiangiogenic therapy, chemotherapy, or radiation significantly improved PFS compared to EGFR-TKI alone.
• Combination with radiation showed superior PFS benefits over other treatments.
• Overall survival (OS) was significantly improved only with EGFR-TKI plus pemetrexed/carboplatin or radiation.
• All combination therapies increased the incidence of Grade 3 or higher AEs, with varying toxicity profiles.

Conclusions:

• Combination of EGFR-TKI with radiation or pemetrexed/carboplatin demonstrated the best antitumor effects among first-generation TKI-based treatments.
• Ramucirumab and bevacizumab may be suitable additions to EGFR-TKIs, considering their safety profiles.
• Further research into optimal combination strategies and toxicity management is warranted for advanced NSCLC.